Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. An organic electroluminescent device can have a good lifespan by using the organic electroluminescent compound of the present disclosure.

Abstract: A benzoxazine resin composition is provided. The benzoxazine resin composition includes a benzoxazine resin that is a reaction product of an amine, a phenol, and an aldehyde. Either the amine is a diamine or the phenol is a bisphenol, and the benzoxazine resin has at least one nitrogen-containing crosslinking functional group or pyrocitric functional group. A method of preparing a benzoxazine resin composition is also provided. The method includes reacting an amine, a phenol, and an aldehyde at a temperature of above 60° C., for 1 h to 5 days to form a benzoxazine resin. The benzoxazine resin has at least one nitrogen-containing crosslinking functional group or pyrocitric functional group, and either the amine is a diamine or the phenol is a bisphenol. Also provided is a cured resin made from the benzoxazine resin composition.

Abstract: A curable composition includes a polymer having a terminal unit. The curable composition also includes a monomer polymerizable with the terminal unit of the polymer. The curable composition additionally includes an inorganic particle capable of absorbing moisture.

Abstract: A degradable resin composition comprising at least one benzoxazine group in a backbone or as an endcap and at least one cleavable covalent bond is provided. Also provided is a thermoset composition comprising a cured benzoxazine-based resin composition including at least one imine group. A degradable resin composition comprising at least one benzoxazine group in a backbone or an endcap, at least one acetal group, and at least one acrylate group is also provided. A method of recycling a resin composition includes providing a cured polymer resin composite which comprises a cured benzoxazine-based resin composition including at least one cleavable covalent bond, and fibers. The method then includes exposing the cured polymer resin composite to an acid, thereby cleaving the at least one cleavable covalent bond to produce a degraded polymer resin, and removing the fibers from the degraded polymer resin.

Abstract: Hybrid organic/inorganic coating compositions of nanometer thickness are described, where the organic layer is a clay-containing layer comprising a clay and a hydrophilic polymer and the inorganic layer is a metal-containing layer comprising a metal with a refractive index greater than 1.5, where the coating compositions allow for the generation and tenability of iridescent color through control of the coat thickness.

Abstract: The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.

Abstract: Hybrid organic/inorganic coating compositions of nanometer thickness are described, where the organic layer is a clay-containing layer comprising a clay and a hydrophilic polymer and the inorganic layer is a metal-containing layer comprising a metal with a refractive index greater than 1.5, where the coating compositions allow for the generation and tenability of iridescent color through control of the coat thickness.

Abstract: The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.